Rivastigmine HEXAL: Uses, Dosage & Side Effects
A dual cholinesterase inhibitor prescribed for mild to moderately severe Alzheimer's disease dementia and dementia associated with idiopathic Parkinson's disease in adults
Rivastigmine HEXAL is a generic capsule preparation of rivastigmine, a dual cholinesterase inhibitor used to treat mild to moderately severe dementia in Alzheimer's disease and dementia associated with Parkinson's disease. Manufactured by Hexal AG, part of the Sandoz generics division of Novartis, Rivastigmine HEXAL is bioequivalent to the original brand Exelon and works by blocking two enzymes – acetylcholinesterase and butyrylcholinesterase – that degrade the neurotransmitter acetylcholine. By prolonging cholinergic signaling in the brain, it may help improve memory, attention, daily functioning, and behavior in affected patients. Available as hard capsules in four strengths (1.5 mg, 3 mg, 4.5 mg, 6 mg), it is a prescription-only medicine taken twice daily with food.
Quick Facts: Rivastigmine HEXAL
Key Takeaways
- Rivastigmine HEXAL is a dual cholinesterase inhibitor that blocks both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), raising acetylcholine levels in the brain to help stabilize cognition in mild to moderate Alzheimer's disease and Parkinson's disease dementia.
- Treatment begins at 1.5 mg twice daily and is escalated in 1.5 mg increments every 2–4 weeks based on tolerance, to a typical effective range of 3–6 mg twice daily and a maximum of 6 mg twice daily (12 mg/day).
- Gastrointestinal side effects – nausea, vomiting, diarrhea, anorexia and weight loss – are the most common adverse reactions, especially during dose titration, and often settle as the body adapts.
- Rivastigmine HEXAL must not be combined with metoclopramide or other cholinesterase inhibitors, and caution is required with beta-blockers, anticholinergics, and QT-prolonging drugs.
- If doses are missed for more than three consecutive days, treatment must be restarted at the lowest dose after consulting a physician to prevent severe cholinergic adverse effects on resumption.
What Is Rivastigmine HEXAL and What Is It Used For?
Rivastigmine HEXAL contains the active substance rivastigmine hydrogen tartrate, a member of the pharmacological class known as cholinesterase inhibitors. This drug class is the most widely used symptomatic treatment for Alzheimer's disease globally and has been approved by regulatory authorities including the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) for more than two decades. Rivastigmine HEXAL is a generic product manufactured by Hexal AG (a Sandoz company within the Novartis Group) and is therapeutically interchangeable with the originator brand Exelon, having been approved through the established EU generic pathway requiring demonstration of pharmaceutical equivalence and bioequivalence.
Rivastigmine occupies a distinctive position within the cholinesterase inhibitor class because, unlike donepezil and galantamine, it is a dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The clinical importance of this dual activity has become clearer with advances in neuropathology: while AChE activity decreases as Alzheimer's disease progresses, BuChE activity increases in cortical regions and is concentrated in the neuritic plaques and neurofibrillary tangles characteristic of the disease. By inhibiting both enzymes, rivastigmine may provide a more sustained cholinergic benefit as disease progresses, particularly in moderate stages.
In the brain of a person with Alzheimer's disease or Parkinson's disease dementia, specific populations of nerve cells, particularly cholinergic neurons projecting from the basal forebrain to the cortex and hippocampus, gradually die. This neuronal loss depletes the neurotransmitter acetylcholine, which plays a central role in attention, working memory, episodic memory encoding, and executive function. The severity of cholinergic deficit correlates closely with the severity of cognitive and functional decline, which forms the scientific rationale for cholinesterase inhibitor therapy. By blocking the enzymes that degrade acetylcholine, rivastigmine prolongs cholinergic neurotransmission at surviving synapses, partially compensating for the lost cholinergic cells.
It is important to understand the realistic goals of treatment. Rivastigmine HEXAL does not cure Alzheimer's disease or Parkinson's disease dementia, nor does it halt the underlying neurodegenerative process. Rather, it is a symptomatic therapy that aims to stabilize or modestly improve cognition, activities of daily living, and global function for a period of months to years. In placebo-controlled clinical trials and meta-analyses, rivastigmine has consistently produced small but clinically meaningful improvements on standardized cognitive assessment scales such as the Alzheimer's Disease Assessment Scale – Cognitive Subscale (ADAS-Cog), and caregivers often report preserved function in everyday tasks such as medication management, personal hygiene, and social interaction.
Rivastigmine HEXAL is specifically approved for two indications in adult patients:
- Mild to moderately severe Alzheimer's disease dementia: Alzheimer's disease is the most common cause of dementia worldwide, accounting for approximately 60–70% of all dementia cases according to the World Health Organization. More than 55 million people live with dementia globally, with nearly 10 million new cases diagnosed each year. Alzheimer's is a progressive neurodegenerative disorder characterized by a gradual decline in memory, language, orientation, calculation, learning capacity, comprehension and judgment. Rivastigmine is indicated for the mild to moderately severe stages (Mini-Mental State Examination scores typically 10–26), the stages in which the cholinergic deficit is prominent and cholinesterase inhibition can produce measurable benefit.
- Dementia associated with idiopathic Parkinson's disease: Parkinson's disease is a neurodegenerative disorder best known for its motor symptoms (tremor, rigidity, bradykinesia and postural instability), but cognitive impairment and dementia are frequent later-stage complications. Parkinson's disease dementia (PDD) affects approximately 20–40% of patients with Parkinson's disease and is characterized by prominent deficits in attention, executive function, visuospatial ability and memory, often accompanied by visual hallucinations and fluctuating cognition. Rivastigmine is the only cholinesterase inhibitor with an explicit EMA approval for PDD, supported by the large randomized EXPRESS trial (Emre et al., New England Journal of Medicine 2004), which demonstrated significant improvements in cognition and activities of daily living over 24 weeks of treatment.
Butyrylcholinesterase plays a minor role in cholinergic neurotransmission in the healthy adult brain, but its activity rises as Alzheimer's disease progresses. By inhibiting both AChE and BuChE, rivastigmine may sustain its effect at a stage when AChE-selective drugs (donepezil, galantamine) lose some of their pharmacological substrate. This theoretical advantage is one reason clinicians sometimes switch patients who fail or lose response on a selective AChE inhibitor to rivastigmine.
Rivastigmine HEXAL is specifically the oral capsule formulation of rivastigmine, taken twice daily with food. A transdermal patch formulation of rivastigmine is also available (from other manufacturers), offering steadier plasma concentrations and generally better gastrointestinal tolerability, which can be considered for patients who struggle with the dose titration of the oral form or who have swallowing difficulties. Your doctor will help determine which formulation best matches your clinical situation, care setting, and preferences.
What Should You Know Before Taking Rivastigmine HEXAL?
Before Rivastigmine HEXAL is prescribed, your healthcare provider should review your full medical history, current medications, allergies, and baseline weight. Certain conditions require additional caution or make rivastigmine unsuitable. Understanding these before starting therapy is essential for safe use.
Contraindications
There are specific situations in which Rivastigmine HEXAL must not be used. These absolute contraindications reflect an unacceptable risk of serious harm:
- Hypersensitivity: Do not take Rivastigmine HEXAL if you are allergic to rivastigmine, to other carbamate derivatives, or to any of the capsule excipients (listed in detail in the "What Does Rivastigmine HEXAL Contain?" section below). Symptoms of a hypersensitivity reaction can range from rash and itching to severe angioedema, bronchospasm, or anaphylaxis, and require immediate medical attention.
- Previous severe skin reaction to a rivastigmine patch: If you previously used a rivastigmine transdermal patch and experienced a reaction that spread beyond the patch area (disseminated allergic contact dermatitis), or had an intense local reaction with blistering, increasing skin inflammation, or edema that did not resolve within 48 hours of removing the patch, you must not switch to Rivastigmine HEXAL capsules. In these patients, systemic rivastigmine exposure could trigger a severe generalized hypersensitivity reaction.
Warnings and Precautions
Before and during treatment with Rivastigmine HEXAL, inform your doctor if any of the following conditions apply, as they may require closer monitoring, dose adjustment, or alternative therapy:
- Cardiac conduction disorders: If you have or have ever had an irregular or slow heartbeat (sick sinus syndrome, atrioventricular block), a congenital long-QT syndrome, a family history of QTc prolongation or torsades de pointes, or low blood levels of potassium or magnesium. Cholinesterase inhibitors have vagotonic effects that can cause bradycardia, syncope and rarely heart block, and rivastigmine may unmask or exacerbate pre-existing conduction disease. A baseline electrocardiogram is reasonable in patients with a cardiac history.
- Active or previous peptic ulcer disease: Cholinesterase inhibitors increase gastric acid secretion through central and peripheral cholinergic mechanisms. Patients with active or healed gastric or duodenal ulcers, or those taking concurrent non-steroidal anti-inflammatory drugs (NSAIDs), are at increased risk of ulceration and upper gastrointestinal bleeding. Gastroprotective therapy (e.g., a proton pump inhibitor) may be appropriate.
- Urinary obstruction: Pre-existing bladder outflow obstruction, benign prostatic hyperplasia with obstructive symptoms, or neurogenic bladder can be worsened by rivastigmine's cholinergic effects on detrusor smooth muscle, potentially precipitating urinary retention or urgency.
- Seizure disorders: Cholinergic drugs may lower seizure threshold and can occasionally precipitate generalized seizures. Seizures are themselves a late manifestation of Alzheimer's disease, so the causal relationship can be difficult to establish, but a history of epilepsy warrants additional caution.
- Asthma and chronic obstructive pulmonary disease (COPD): Cholinergic stimulation increases bronchial secretions and bronchomotor tone. Patients with active asthma, severe COPD, or other serious respiratory disease may experience bronchoconstriction, increased sputum production, or impaired respiratory function.
- Hepatic and renal impairment: Rivastigmine is primarily eliminated through cholinesterase-mediated hydrolysis with subsequent renal excretion of the inactive metabolite NAP226-90. Although pharmacokinetic changes in renal impairment are modest, patients with severe renal or hepatic impairment may have increased drug exposure and adverse effects; slower titration is often prudent.
- Low body weight: Patients weighing less than 50 kg, particularly frail elderly women, experience adverse effects more frequently and lose significantly more weight during treatment. Baseline and regular weight monitoring are essential, and titration may need to be slower with a lower maintenance dose.
- Extrapyramidal symptoms: In patients with Parkinson's disease dementia, rivastigmine can worsen tremor, rigidity, or motor fluctuations. These effects are usually modest but should be monitored, and the drug may need to be stopped if motor function deteriorates substantially.
If you have not taken Rivastigmine HEXAL for more than three consecutive days, do not simply resume your previous dose. Restarting at the prior maintenance dose after an interruption can precipitate severe nausea, vomiting, diarrhea, hypotension, bradycardia and, very rarely, esophageal rupture from violent vomiting. Contact your doctor, who will typically restart treatment at 1.5 mg twice daily and re-titrate gradually.
Pregnancy and Breastfeeding
Rivastigmine HEXAL is almost exclusively prescribed to elderly patients, and pregnancy is therefore uncommon during treatment. However, in the rare circumstance that a woman of childbearing potential is treated (for example, an atypical young-onset dementia or a rare inherited condition), the following applies: there are limited human data on rivastigmine use during pregnancy. Animal reproduction studies have not demonstrated direct teratogenic effects, but reduced maternal body weight and fetal weight have been observed at high doses. Rivastigmine HEXAL should not be used during pregnancy unless the anticipated maternal benefit clearly outweighs the potential fetal risk, and only after specialist consultation.
Animal studies have shown that rivastigmine is excreted in breast milk. It is not known whether it appears in human breast milk. Because of the theoretical risk of cholinergic adverse effects in the breastfed infant, breastfeeding is not recommended in women taking Rivastigmine HEXAL. If the drug is judged essential, breastfeeding should be discontinued.
Driving and Operating Machinery
Your doctor will advise you whether your underlying disease allows safe operation of a motor vehicle or complex machinery. Rivastigmine HEXAL can cause dizziness, drowsiness, syncope and, in some patients, hallucinations or confusion, particularly at the start of therapy and during dose escalation. Patients should not drive, operate machinery, or undertake other safety-critical activities until they know how the medicine affects them. In addition, dementia itself independently impairs driving ability, and formal driving assessment is often appropriate regardless of medication.
How Does Rivastigmine HEXAL Interact with Other Drugs?
Rivastigmine is metabolized almost exclusively by esterase-mediated hydrolysis at its site of action rather than by hepatic cytochrome P450 enzymes. This pharmacokinetic profile minimizes the potential for drug–drug interactions mediated through CYP inhibition or induction. However, because rivastigmine exerts its pharmacological action by enhancing cholinergic neurotransmission, several clinically important pharmacodynamic interactions exist, particularly with other drugs that affect the cholinergic system, the heart, or the gastrointestinal tract. Always give your doctor and pharmacist a complete list of prescription medicines, over-the-counter products, herbal remedies and supplements.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Other cholinesterase inhibitors (donepezil, galantamine) | Additive cholinergic effects; increased risk of severe gastrointestinal and cardiac adverse reactions | Do not combine – use only one cholinesterase inhibitor at a time |
| Metoclopramide (antiemetic/prokinetic) | Risk of severe extrapyramidal reactions including joint stiffness, hand tremor, torticollis, and involuntary movements | Avoid combination; select an alternative antiemetic (e.g., ondansetron after specialist advice) |
| Beta-blockers (atenolol, metoprolol, propranolol, bisoprolol) | Additive bradycardia, potential atrioventricular block, and syncope or falls | Use with caution; monitor heart rate and blood pressure; cardiology consultation in complex cases |
| QT-prolonging drugs (sotalol, amiodarone, haloperidol, certain macrolides and fluoroquinolones) | Theoretical additive prolongation of QTc interval; risk of torsades de pointes | Use with caution; consider ECG monitoring and electrolyte correction |
| Succinylcholine-type muscle relaxants (used during anesthesia) | Prolongation of neuromuscular blockade; potentially delayed recovery from paralysis | Inform anesthesiologist before surgery; dose of relaxant should be adjusted |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Anticholinergic medications (oxybutynin, tolterodine, benztropine, hyoscine, first-generation antihistamines, tricyclic antidepressants) | Pharmacological antagonism; may reduce the cognitive benefit of rivastigmine and worsen confusion | Avoid or minimize; review indication for each anticholinergic drug and consider alternatives |
| NSAIDs (ibuprofen, naproxen, diclofenac, aspirin) | Additive risk of gastric ulceration and upper gastrointestinal bleeding through independent mechanisms | Use with caution; consider gastroprotection with a proton pump inhibitor and avoid prolonged use |
| Cholinergic agonists (bethanechol, pilocarpine) | Additive cholinergic stimulation – diarrhea, bradycardia, bronchospasm, excessive secretions | Use with caution; monitor for cholinergic symptoms |
| Digoxin | Rivastigmine does not alter digoxin pharmacokinetics but additive bradycardia is possible | Monitor heart rate; dose changes rarely needed |
| Nicotine | Nicotine increases rivastigmine oral clearance by approximately 23%, potentially reducing exposure | Clinically usually minor; consider if response to treatment is poor in heavy smokers |
Before any surgical procedure that requires general anesthesia, it is essential to tell the surgeon and anesthesiologist that you are taking Rivastigmine HEXAL. The drug inhibits plasma cholinesterase and can prolong the neuromuscular blocking effects of depolarizing muscle relaxants such as succinylcholine, potentially causing delayed reversal of paralysis and respiratory complications. With appropriate pre-operative communication, the anesthetic technique can be adjusted – for example, by choosing a non-depolarizing agent or reducing the succinylcholine dose – and the risk is easily manageable.
Unlike many other long-term medications, rivastigmine does not interact clinically with drugs metabolized through the cytochrome P450 enzyme system. This means patients taking rivastigmine can usually continue their warfarin, antiepileptics, statins, or proton pump inhibitors at unchanged doses, although individual clinical judgment always applies. Rivastigmine also has no clinically relevant interactions with commonly used psychotropic drugs such as selective serotonin reuptake inhibitors or memantine, the latter of which is frequently co-prescribed in moderate-to-severe Alzheimer's disease.
What Is the Correct Dosage of Rivastigmine HEXAL?
Always take Rivastigmine HEXAL exactly as your doctor has prescribed. Dosing is individualized on the basis of tolerability and clinical response, and slow upward titration is the single most important strategy for minimizing the gastrointestinal side effects that are the most common reason patients stop therapy. Your physician will use the lowest dose at which you obtain benefit and tolerate the medication.
Adults
Starting Dose
Dose: 1.5 mg twice daily (total 3 mg/day)
Duration at this step: At least 2 weeks before any dose increase
Starting low allows the gastrointestinal system to adapt to cholinergic stimulation. Take one capsule with breakfast and one with the evening meal – always with food, which both reduces nausea and smooths the absorption profile.
Dose Titration
Increments: Increase by 1.5 mg per dose at intervals of at least 2–4 weeks, according to tolerance
Titration ladder: 1.5 mg → 3 mg → 4.5 mg → 6 mg twice daily
Each step is held at least 2 weeks (often 4 weeks in clinical practice). If troublesome side effects emerge during an increase, your doctor may delay the next step, return to the previous dose, or pause therapy briefly before resuming at the lower dose.
Maintenance Dose
Effective therapeutic range: 3 mg to 6 mg twice daily (6–12 mg/day)
Maximum dose: 6 mg twice daily (12 mg/day)
Higher doses within the recommended range are generally associated with greater benefit but also more adverse effects. Your physician will reassess cognition, global function and tolerability at each follow-up and consider dose reduction if the balance becomes unfavorable.
Children and Adolescents
Rivastigmine HEXAL is not indicated for use in children or adolescents under 18 years of age. The conditions treated by rivastigmine – Alzheimer's disease dementia and Parkinson's disease dementia – are diseases of older adults, and there is no established pediatric indication. Paediatric use is therefore considered off-label and is not supported by adequate safety or efficacy data.
Elderly Patients
The overwhelming majority of patients prescribed rivastigmine are over 65 years of age, and most clinical trial experience is in this population. No specific dose adjustment is required based on age alone. However, elderly patients – particularly those aged 85 years or older – are more vulnerable to adverse effects, including gastrointestinal symptoms, weight loss, orthostatic hypotension and falls. Careful titration with prolonged intervals between increases, regular weight monitoring, attention to hydration, and review of concurrent medications (to avoid anticholinergic polypharmacy) are all essential. Patients with low body weight (under 50 kg) may need slower titration and a lower maintenance dose.
Hepatic and Renal Impairment
In patients with mild to moderate hepatic impairment or mild to moderate renal impairment, no formal dose adjustment is recommended, but exposure can be modestly increased; slower titration is appropriate. There is limited experience in severe hepatic or severe renal impairment, and rivastigmine should only be used with extra caution and close monitoring in these populations. Adverse effects that appear may be managed by reducing the dose or returning to the previous titration step.
How to Take Rivastigmine HEXAL
- Twice daily – one capsule in the morning and one in the evening, at consistent times to support adherence.
- Always with food – food slows absorption slightly, reduces peak plasma concentrations, and substantially reduces nausea.
- Swallow the capsule whole with a glass of water. Do not open, crush, or chew the capsules.
- Tell caregivers about the medication, as reminders and supervision are often essential in dementia.
- Do not stop abruptly without medical advice. Continuation allows you to maintain any clinical benefit achieved.
Missed Dose
If you forget an individual dose, wait until your next scheduled dose time and take it as usual – do not double-dose. If you have not taken Rivastigmine HEXAL for more than three consecutive days, contact your doctor before restarting: resuming the previous dose after a lapse of more than three days can provoke severe nausea, vomiting and hypotension. Your physician will generally restart therapy at 1.5 mg twice daily and titrate upward gradually.
Overdose
If more Rivastigmine HEXAL is taken than prescribed, contact your doctor, a poison control center, or emergency services immediately. Doses of up to 46 mg have been taken in case reports, typically producing transient nausea, vomiting, diarrhea, salivation, bradycardia, hypotension and, in severe cases, seizures and collapse. A cholinergic crisis can occasionally occur, characterized by extreme muscle weakness or paralysis, profuse secretions, miosis, and respiratory failure. Treatment is supportive. Because the elimination half-life of rivastigmine is only 1–2 hours but cholinesterase inhibition lasts about 9 hours, observation for at least 24 hours is appropriate in significant overdose. Atropine may be used as an antidote for severe bradycardia and cholinergic symptoms.
What Are the Side Effects of Rivastigmine HEXAL?
Like all medicines, Rivastigmine HEXAL can cause side effects, although not everybody experiences them. Adverse reactions are most common during the first weeks of treatment and during dose escalation, and they typically settle as the body adapts. When side effects are troublesome, the treating physician may slow titration, temporarily reduce the dose, or advise taking the capsule with a larger meal. Frequencies below are classified according to the EMA standard: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).
Very Common
- Dizziness
- Decreased appetite (anorexia)
- Nausea
- Vomiting
- Diarrhea
Common
- Anxiety and agitation
- Excessive sweating
- Headache
- Heartburn (dyspepsia)
- Abdominal pain
- Weight loss
- Feeling of restlessness or mild confusion
- Fatigue or asthenia
- General feeling of being unwell (malaise)
- Tremor
- Drowsiness (somnolence)
- Nightmares and vivid dreams
Uncommon
- Depression
- Insomnia
- Syncope (fainting) and accidental falls
- Elevated liver function tests (AST/ALT)
Rare and Very Rare
- Angina pectoris (chest pain)
- Skin rash and pruritus (itching)
- Seizures (convulsions)
- Gastric and duodenal ulcers
- Hypertension
- Urinary tract infection
- Visual or auditory hallucinations
- Cardiac arrhythmias (bradycardia, tachycardia, atrioventricular block, atrial fibrillation)
- Gastrointestinal bleeding (hematemesis, melena)
- Pancreatitis (severe upper-abdominal pain with nausea and vomiting)
- Worsening of Parkinsonian symptoms (rigidity, bradykinesia)
- Severe vomiting with risk of esophageal rupture (Boerhaave syndrome)
- Dehydration due to fluid loss
- Hepatitis and elevated bilirubin (jaundice, dark urine, fatigue)
- Aggression and restlessness
- Pisa syndrome (tonic lateral flexion of the trunk)
Side Effect Profile in Parkinson's Disease Dementia
Patients with dementia associated with Parkinson's disease have a somewhat different side-effect profile, reflecting their underlying disease. In this population the following additional adverse reactions may occur more frequently:
- Very common: Worsening of tremor, accidental falls.
- Common: Anxiety, restlessness, bradycardia and tachycardia, sleep disturbances, hypersalivation, dehydration, dyskinesia, worsening of Parkinson's disease motor symptoms (rigidity, bradykinesia, muscle weakness, gait disturbance), hallucinations, depression, hypertension.
- Uncommon: Irregular heart rhythm, poor motor control, orthostatic hypotension.
Managing Common Side Effects
Many patients experience nausea, loss of appetite, or vomiting in the first weeks of treatment or after a dose increase. The following practical strategies are recommended by geriatric pharmacology guidelines:
- Always take the capsule with a full meal, not just a snack.
- Avoid lying down for at least 30 minutes after a dose.
- Prefer small, frequent meals over large ones during titration.
- Monitor weight weekly during titration and report sustained weight loss (≥5% over a month) to your doctor.
- Stay well hydrated; dehydration worsens both gastrointestinal symptoms and cognition.
Contact your doctor or seek urgent care if you develop severe or persistent vomiting, signs of dehydration (dry mouth, reduced urination, dark urine, dizziness when standing), chest pain, fainting, a new seizure, signs of liver injury (yellowing of skin or eyes, very dark urine, right upper quadrant pain), severe abdominal pain, black or bloody stools, or blood in vomit. These can indicate serious adverse reactions requiring rapid evaluation.
Reporting suspected adverse reactions: If you experience any side effect, including those not listed above, talk to your doctor, pharmacist or nurse. Reporting suspected adverse reactions to your national pharmacovigilance authority (for example the MHRA Yellow Card scheme in the UK, the FDA MedWatch program in the US, or the national competent authority within the EMA network) helps regulators monitor the safety of medicines and protect future patients.
How Should You Store Rivastigmine HEXAL?
Proper storage is essential to preserve the potency and safety of any medicine. Rivastigmine HEXAL should be stored in a cool, dry place at a temperature not exceeding 25°C (77°F). Avoid storing it in bathrooms, kitchens, or near heat sources, as humidity and temperature extremes can damage the capsules. Keep the blister packs inside the outer carton or the bottle tightly closed until you are ready to take a dose; this protects the capsules from moisture and light.
Keep Rivastigmine HEXAL out of the sight and reach of children. Even a small accidental ingestion of rivastigmine by a child – a few capsules – can produce a serious cholinergic crisis, with vomiting, bradycardia, salivation, muscle weakness and respiratory compromise. If accidental ingestion occurs, seek emergency medical care immediately and take the packaging with you so that the dose taken can be estimated.
Do not use Rivastigmine HEXAL after the expiry date printed on the carton and blister pack. The expiry date refers to the last day of the stated month. Expired capsules may be less effective or, in rare cases, unsafe. If you are travelling, check the local temperature conditions and avoid leaving the medicine in a hot car or in direct sunlight.
Do not dispose of unused or expired rivastigmine capsules in household waste or wastewater. Return them to your community pharmacist, hospital pharmacy, or drug take-back program. Pharmaceutical active ingredients in landfill and water systems are a growing environmental concern, and responsible return is a small but meaningful contribution to environmental stewardship.
What Does Rivastigmine HEXAL Contain?
Each Rivastigmine HEXAL capsule contains rivastigmine in the form of rivastigmine hydrogen tartrate as the active substance. The capsules are available in four strengths, distinguishable by color coding to reduce the risk of dosing errors:
| Strength | Capsule Color | Capsule Contents |
|---|---|---|
| 1.5 mg | Yellow cap and yellow body | Off-white to slightly yellowish powder |
| 3 mg | Orange cap and orange body | Off-white to slightly yellowish powder |
| 4.5 mg | Red cap and red body | Off-white to slightly yellowish powder |
| 6 mg | Red cap and orange body | Off-white to slightly yellowish powder |
The inactive ingredients (excipients) are:
- Capsule contents: Magnesium stearate (lubricant), colloidal anhydrous silica (glidant), hypromellose (binder), microcrystalline cellulose (filler/diluent). These pharmaceutical excipients ensure uniform dosing, flow, and release of the active substance.
- Capsule shell: Gelatin (primary structural material), titanium dioxide (E171, white colorant), and iron oxide colorants (E172, yellow and/or red depending on strength). Printing ink may contain shellac and iron oxides.
Rivastigmine HEXAL capsules are typically packaged in aluminum/PVC or aluminum/PVC-PVDC blister packs of 28, 56, 84, 112 or 120 capsules, and in some countries in HDPE bottles of 250 capsules. Not all pack sizes are marketed in every country.
Rivastigmine HEXAL is manufactured and distributed by Hexal AG, a pharmaceutical company headquartered in Holzkirchen, Germany. Hexal is part of Sandoz, the generics and biosimilars division of Novartis. The product is authorized through national and decentralized regulatory procedures in multiple European countries and is pharmaceutically equivalent to the originator brand Exelon (Novartis). Marketing authorisation numbers and local product codes vary by country and are available in the national product information and from your dispensing pharmacist.
Frequently Asked Questions
Rivastigmine HEXAL is a generic product containing exactly the same active substance (rivastigmine hydrogen tartrate) in the same strengths and dosage form as the originator brand Exelon. It has been approved on the basis of demonstrated pharmaceutical equivalence and bioequivalence to Exelon, meaning it delivers comparable blood levels of rivastigmine over time. Clinical efficacy and safety are therefore expected to be the same. Differences between the two products are limited to non-active aspects such as excipients, capsule colors, and branded packaging. Rivastigmine HEXAL is generally substantially less expensive, which has made it an important option in publicly funded healthcare systems.
Yes. Rivastigmine and memantine work through different mechanisms – rivastigmine increases brain acetylcholine, whereas memantine modulates glutamate activity at the NMDA receptor – and combination therapy is commonly used in moderate to severe Alzheimer's disease. Several randomized trials and meta-analyses suggest that combining a cholinesterase inhibitor with memantine provides modest additional benefits on cognition, global function and behavioral symptoms compared with either drug alone, with a favorable safety profile. Your neurologist or geriatrician will decide whether combination therapy is appropriate for your clinical stage.
Meaningful clinical effects usually become apparent only after the therapeutic dose has been reached and maintained for several weeks. Because titration is slow – a minimum of two weeks at each dose level – most patients take 12 to 26 weeks (3–6 months) from the first capsule to reach the final dose and experience its full effect. Some caregivers notice subtle improvements in attention, alertness, conversational engagement, or activities of daily living within the first one to two months, but individual response varies widely. Formal reassessment at 3–6 months typically guides decisions about continuing treatment.
Caregivers are central to successful rivastigmine therapy in dementia. Key points include: ensure each dose is taken twice daily with a proper meal and at consistent times; watch for nausea, vomiting, diarrhea, and weight loss, and report persistent or severe symptoms; keep a medication diary, especially during titration; do not double up missed doses, and call the doctor if doses have been missed for more than three days; observe for changes in alertness, behavior, sleep, hallucinations, or gait; keep the medication in its original packaging and out of reach of visiting children; and attend review appointments to discuss whether treatment is still helpful. Remember that rivastigmine is a supportive therapy, not a cure – success is often measured by stabilisation rather than improvement.
Both contain the same active substance but are different formulations. Rivastigmine HEXAL is an oral capsule taken twice daily with meals, while the rivastigmine transdermal patch is applied to the skin once a day. The patch provides smoother, more steady plasma drug levels, which generally reduces gastrointestinal side effects such as nausea and vomiting; it also simplifies dosing for patients with swallowing difficulties. However, the patch can cause local skin reactions, and occasionally severe dermatitis. Some patients respond better to one formulation than to the other, and clinicians may switch forms if a patient has tolerability problems. Your doctor can advise on the preferred option for your circumstances.
No. Rivastigmine HEXAL is not licensed for the prevention of Alzheimer's disease and has not been shown in randomized controlled trials to delay the onset of dementia in people with normal cognition or mild cognitive impairment. It is approved only for patients with an established diagnosis of mild to moderately severe Alzheimer's disease dementia or Parkinson's disease dementia. Disease-modifying therapies targeting amyloid plaques (such as certain monoclonal antibodies) and tau pathology are being developed and some are now approved in selected regions, but cholinesterase inhibitors remain symptomatic treatments that address the cholinergic deficit rather than the underlying neurodegeneration.
Decisions to continue, change or stop rivastigmine are individualized and should involve the patient (when possible) and family. Continuation is usually appropriate while the patient still experiences benefit and tolerates the drug. Discontinuation is considered when: the patient has reached very severe dementia and no longer interacts with their environment; serious or intolerable side effects develop; there is significant weight loss; there is clear evidence of cardiac or other contraindications; or the patient is in terminal care. Abrupt stopping is generally avoided because some patients deteriorate after withdrawal; many clinicians taper the dose over two to four weeks and monitor for worsening cognition or behavior.
References
- European Medicines Agency (EMA). Rivastigmine – Summary of Product Characteristics. Last updated 2025. Available at: www.ema.europa.eu
- Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews. 2015;(4):CD001191. doi:10.1002/14651858.CD001191.pub4
- National Institute for Health and Care Excellence (NICE). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Technology Appraisal Guidance [TA217]. Updated 2023. Available at: www.nice.org.uk/guidance/ta217
- Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine. 2004;351(24):2509-2518. doi:10.1056/NEJMoa041470
- World Health Organization (WHO). Dementia Fact Sheet. 2023. Available at: www.who.int
- American Academy of Neurology (AAN). Practice Parameter Update: Mild Cognitive Impairment and Dementia – Evidence-based Guideline. Updated 2024.
- Grossberg GT, Sadowsky C, Olin JT. Rivastigmine transdermal system for Alzheimer's disease and Parkinson's disease dementia. Annals of the New York Academy of Sciences. 2010;1199:167-174. doi:10.1111/j.1749-6632.2009.05371.x
- U.S. Food and Drug Administration (FDA). Exelon (rivastigmine tartrate) Prescribing Information. Reference ID: 4756254.
- British National Formulary (BNF). Rivastigmine. Joint Formulary Committee, London: BMJ Group and Pharmaceutical Press. Updated 2025.
- Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease – rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry. 2007;22(5):456-467.
- Gauthier S, Rosa-Neto P, Morais JA, et al. World Alzheimer Report 2021: Journey through the diagnosis of dementia. Alzheimer's Disease International, London. 2021.
Editorial Team
This article has been written and reviewed by medical professionals to ensure clinical accuracy and adherence to current evidence-based guidelines.
Medical Content
iMedic Medical Editorial Team – Specialists in Neurology, Geriatric Medicine, and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel following WHO, EMA, FDA, and NICE guidelines
Evidence Standard
Level 1A – Systematic reviews and meta-analyses of randomized controlled trials (GRADE framework)
Last Review
December 29, 2025 – Next scheduled review within 12 months
Conflict of Interest Declaration: The iMedic editorial team has no financial relationships with pharmaceutical companies, including Hexal AG, Sandoz, or Novartis. All content is independently produced without commercial sponsorship or advertising influence. Our editorial standards are published at iMedic Editorial Standards.